Text of section effective on April 01, 2025

Sec. 549.0205.  CONSIDERATIONS FOR INCLUDING DRUG ON PREFERRED DRUG LISTS.  (a)  In making a decision regarding the placement of a drug on each of the preferred drug lists adopted under this subchapter, the commission shall consider:
(1)  the board's recommendations under Section 549.0309;
(2)  the drug's clinical efficacy;
(3)  the price of competing drugs after deducting any federal and state rebate amounts; and
(4)  program benefit offerings solely or in conjunction with rebates and other pricing information.
(b)  The commission shall consider including on a preferred drug list:
(1)  multiple methods of delivery within each drug class, including liquid, capsule, and tablet, including an orally disintegrating tablet; and
(2)  all strengths and dosage forms of a drug.
Added by Acts 2023, 88th Leg., R.S., Ch. 769 (H.B. 4611), Sec. 1.01, eff. April 1, 2025.